Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 548

1.

The combination of L-4F and simvastatin stimulate cholesterol efflux and related proteins expressions to reduce atherosclerotic lesions in apoE knockout mice.

Ying R, Yuan Y, Qin YF, Tian D, Feng L, Guo ZG, Sun YX, Li MX.

Lipids Health Dis. 2013 Dec 8;12:180. doi: 10.1186/1476-511X-12-180.

PMID:
24314261
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

ApoB versus non-HDL-cholesterol: diagnosis and cardiovascular risk management.

de Nijs T, Sniderman A, de Graaf J.

Crit Rev Clin Lab Sci. 2013 Nov;50(6):163-71. doi: 10.3109/10408363.2013.847897. Review.

PMID:
24295059
[PubMed - indexed for MEDLINE]
3.

Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.

Pang J, Chan DC, Hamilton SJ, Tenneti VS, Watts GF, Barrett PH.

Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):427-32. doi: 10.1161/ATVBAHA.113.302019. Epub 2013 Nov 27.

PMID:
24285582
[PubMed - indexed for MEDLINE]
4.

Therapeutic approaches to the regulation of metabolism of high-density lipoprotein. Novel HDL-directed pharmacological intervention and exercise.

Zhang B, Kawachi E, Miura S, Uehara Y, Matsunaga A, Kuroki M, Saku K.

Circ J. 2013;77(11):2651-63. Epub 2013 Oct 10. Review.

PMID:
24107398
[PubMed - indexed for MEDLINE]
Free Article
5.

The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome.

Li XP, Gong HR, Huang XS, Huang WY, Zhao SP.

Lipids Health Dis. 2013 Sep 9;12:133. doi: 10.1186/1476-511X-12-133.

PMID:
24016248
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.

Mora S, Glynn RJ, Ridker PM.

Circulation. 2013 Sep 10;128(11):1189-97. doi: 10.1161/CIRCULATIONAHA.113.002671. Epub 2013 Sep 3.

PMID:
24002795
[PubMed - indexed for MEDLINE]
7.

A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).

Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH.

Clin Ther. 2013 Sep;35(9):1400-11.e1-3. doi: 10.1016/j.clinthera.2013.07.420. Epub 2013 Aug 30.

PMID:
23998969
[PubMed - indexed for MEDLINE]
8.

Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).

Albers JJ, Slee A, O'Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SM.

J Am Coll Cardiol. 2013 Oct 22;62(17):1575-9. doi: 10.1016/j.jacc.2013.06.051. Epub 2013 Aug 21.

PMID:
23973688
[PubMed - indexed for MEDLINE]
9.

Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ.

Circulation. 2013 Oct 1;128(14):1504-12. doi: 10.1161/CIRCULATIONAHA.113.002670. Epub 2013 Aug 21.

PMID:
23965489
[PubMed - indexed for MEDLINE]
10.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.

PMID:
23932901
[PubMed - indexed for MEDLINE]
11.

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF.

Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Review.

PMID:
23932550
[PubMed - indexed for MEDLINE]
Free Article
12.

Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.

Robinson JG, Ballantyne CM, Hsueh WA, Rosen JB, Lin J, Shah AK, Tomassini JE, Lowe RS, Tershakovec AM.

J Clin Lipidol. 2013 Jul-Aug;7(4):292-303. doi: 10.1016/j.jacl.2013.03.007. Epub 2013 Apr 3.

PMID:
23890516
[PubMed - indexed for MEDLINE]
13.

Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.

Farnier M, Guyton JR, Jensen E, Polis AB, Johnson-Levonas AO, Brudi P.

Atherosclerosis. 2013 Aug;229(2):415-22. doi: 10.1016/j.atherosclerosis.2013.05.010. Epub 2013 Jun 5.

PMID:
23880197
[PubMed - indexed for MEDLINE]
14.

A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial.

Barrat E, Zaïr Y, Ogier N, Housez B, Vergara C, Maudet C, Lescuyer JF, Bard JM, Carpentier YA, Cazaubiel M, Peltier SL.

Int J Food Sci Nutr. 2013 Nov;64(7):882-9. doi: 10.3109/09637486.2013.809405. Epub 2013 Jul 2.

PMID:
23815518
[PubMed - indexed for MEDLINE]
15.

Effects of ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg on apolipoprotein B/apolipoprotein A1 in Korean patients with type 2 diabetes mellitus: results of a randomized controlled trial.

Lee JH, Kang HJ, Kim HS, Sohn DW, Oh BH, Park YB.

Am J Cardiovasc Drugs. 2013 Oct;13(5):343-51. doi: 10.1007/s40256-013-0031-6.

PMID:
23728830
[PubMed - indexed for MEDLINE]
16.

Apolipoprotein profiles in subjects with and without peripheral artery disease.

Gardner AW, Alaupovic P, Parker DE, Montgomery PS, Roof A, Casanegra AI.

Vasc Med. 2013 Jun;18(3):129-35. doi: 10.1177/1358863X13489768.

PMID:
23720036
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.

Kurogi K, Sugiyama S, Sakamoto K, Tayama S, Nakamura S, Biwa T, Matsui K, Ogawa H; COMPACT-CAD Investigators.

J Cardiol. 2013 Aug;62(2):87-94. doi: 10.1016/j.jjcc.2013.03.008. Epub 2013 May 11.

PMID:
23672789
[PubMed - indexed for MEDLINE]
Free Article
18.

Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.

Kei A, Liberopoulos E, Tellis K, Rizzo M, Elisaf M, Tselepis A.

Eur J Clin Invest. 2013 Jul;43(7):698-707. doi: 10.1111/eci.12095. Epub 2013 Apr 20.

PMID:
23600368
[PubMed - indexed for MEDLINE]
19.

Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis.

Liu M, Yu Y, Jiang H, Zhang L, Zhang PP, Yu P, Jia JG, Chen RZ, Zou YZ, Ge JB.

Acta Pharmacol Sin. 2013 Jun;34(6):830-6. doi: 10.1038/aps.2013.8. Epub 2013 Apr 8.

PMID:
23564080
[PubMed - indexed for MEDLINE]
20.

Comparison of therapeutic lipid target achievements among high-risk patients in Oman.

Al-Waili K, Al-Zakwani I, Al-Dughaishi T, Baneerje Y, Al-Sabti H, Al-Hashmi K, Farhan H, Habsi KA, Al-Hinai AT, Al-Rasadi K.

Angiology. 2014 May;65(5):430-5. doi: 10.1177/0003319713482572. Epub 2013 Apr 5.

PMID:
23564019
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk